Please assess the completion status of the following clinical trial:

Trial Title: A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is HIV positive~* Patient agrees to use (or have their partner use) birth control as defined by the study doctor~Exclusion Criteria:~* If female, pregnant or breastfeeding~* Patient has used an investigational agent in the last 30 days~* Patient has acute hepatitis~* Patient has received MK0518 (raltegravir) before~* Patient has used another experimental HIV-integrase inhibitor

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): raltegravir

Based on this trial design, predict the completion outcome and termination type (if applicable).